Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other neoplasm 1

Conditions

Melanoma 117Carcinoma, Non-Small-Cell Lung 102Carcinoma, Renal Cell 69Colorectal Neoplasms 46Neoplasm Metastasis 41Squamous Cell Carcinoma of Head and Neck 39Carcinoma, Hepatocellular 38Neoplasms 36Lung Neoplasms 34Stomach Neoplasms 33Urinary Bladder Neoplasms 22Carcinoma, Transitional Cell 21Hodgkin Disease 20Brain Neoplasms 20Pancreatic Neoplasms 18Ovarian Neoplasms 18Prostatic Neoplasms 17Head and Neck Neoplasms 16Colonic Neoplasms 16Skin Neoplasms 15Triple Negative Breast Neoplasms 14Sarcoma 14Glioblastoma 14Adenocarcinoma Of Esophagus 14Carcinoma, Merkel Cell 13Small Cell Lung Carcinoma 12Rectal Neoplasms 12Esophageal Neoplasms 12Breast Neoplasms 12Uveal Melanoma 11

Interventions

toripalimab 1potassium oxonate 1gimeracil 1apatinib 1Tegafur 1Nivolumab 1Gemcitabine 1Capecitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Malignant Neoplasms of Digestive Organs × Nivolumab × 1 year × Clear all
NCT05934331 2025-09-12

A LM-302 Combination With Other Anti-Tumor Therapies Phase ll Study

LaNova Medicines Limited

Phase 2 Recruiting
276 enrolled
Other neoplasm

Malignant Neoplasms of Digestive Organs

Data powered by HemOnc (CC BY 4.0) Colophon âš¡